Why Gilead is Biotech’s Cash Cow, Acquiring Kite

MoneyShow  |

The future is infectious. There will be blood, which means there will be blood-borne viruses, asserts Igor Greenwald, editor of Investing Daily’s Income Millionaire.

Which means Gilead Sciences (GILD) should continue to strike it rich from its leading drug franchises for the treatment of human immunodeficiency virus (HIV) as well as hepatitis C.

Confidence in that last point has been shaken over the last two years as Gilead’s hepatitis C sales tailed off because of its drugs’ success in curing the disease as well as inroads by competitors. As a result, Gilead’s share price slumped from $120 in June 2015 to $64 last month. It has since rallied 18%.

Despite the recent rebound, Gilead remains a compelling opportunity. During the first six months of 2017, the company generated $5.8 billion of net income and used less than a quarter of that to pay dividends yielding an annualized 2.7% at the current share price. Share repurchases consumed $695 million, or another 12% of net income.

And while second-quarter sales were down 8% year-over-year, they rose 10% sequentially, allowing Gilead to increase its full-year sales and profit guidance when it reported the results last week.

Gilead’s $36.5 billion cash pile comfortably exceeds its $26.5 billion in long-term debt.

Its liquid balance sheet and recent sales slump have fueled speculation that the company might make a splashy acquisition in pursuit of growth, and management continues to acknowledge interest in such a transaction. [Gilead announced it would buy Kite Pharma (KITE), a maker of cancer treatments for $11.9 billion August 28.]

But with its shares priced at perhaps 9 times this year’s earnings, Gilead need only stick to its knitting to provide a good long-term return.

While hepatitis C sales have begun to stabilize, the HIV franchise is powering ahead on the strength of new drugs still taking share in growing markets of U.S. as well as Europe.

With near-term risk reduced, the stock’s huge downward momentum broken and a valuation well below that of peers, the time is right to add this cash cow to the portfolio.

Igor Greenwald is chief investment strategist of MLP profits.

Subscribe to Investing Daily’s Income Millionaire here…

About MoneyShow.com: Founded in 1981, MoneyShow is a privately held financial media company headquartered in Sarasota, Florida. As a global network of investing and trading education, MoneyShow presents an extensive agenda of live and online events that attract over 75,000 investors, traders and financial advisors around the world.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.


Symbol Name Price Change % Volume
GILD Gilead Sciences Inc. 63.43 0.80 1.28 7,906,261 Trade



Symbol Last Price Change % Change





















Blockchain in Healthcare - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Digital Health - How Blockchain technology can make health care systems more patient-centric and sustainable